Ensartinib Action Letter and Amendment for NRG-LU003


NRG-LU003: Action Letter for Ensartinib and Amendment 3; protocol version date:  September 9, 2019. Available on the CTSU website.


Accrual of new patients must be suspended until the IRB of record has reviewed and approved the amendment.


Patients currently on study who are receiving ensartinib may continue on study provided they are informed of the new and/or modified risk information.

This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address | Forward Email | Report Abuse